[go: up one dir, main page]

KR930700165A - Contrast agent - Google Patents

Contrast agent

Info

Publication number
KR930700165A
KR930700165A KR1019920702350A KR920702350A KR930700165A KR 930700165 A KR930700165 A KR 930700165A KR 1019920702350 A KR1019920702350 A KR 1019920702350A KR 920702350 A KR920702350 A KR 920702350A KR 930700165 A KR930700165 A KR 930700165A
Authority
KR
South Korea
Prior art keywords
complex
multinuclear
contrast
atom
contrast agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019920702350A
Other languages
Korean (ko)
Inventor
베르그 안
알멘 토르스텐
디에터 크라우트우르스트 클라우스
김숙희
롱베드 팔
클라베니스 조
덕스테드 해랄드
Original Assignee
원본미기재
니코메드 이메이징 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 니코메드 이메이징 에이에스 filed Critical 원본미기재
Publication of KR930700165A publication Critical patent/KR930700165A/en
Ceased legal-status Critical Current

Links

Abstract

내용 없음.No content.

Description

조영제Contrast agent

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (14)

적어도 두개의 콘트라스트(contrast) 증진(enhancing) 원자를 포함하는 생리적으로 허용가능한 다핵(multinuclear) 복합체(complex)와 함께 적어도 하나의 약제학적 담체 또는 부헝제를 포함하는 진단 영상화 조영제(contrast media).Diagnostic imaging contrast medium comprising at least one pharmaceutical carrier or medicament with a physiologically acceptable multinuclear complex comprising at least two contrast enhancing atoms. 제1항에 있어서, 상기 다핵 복합체가 공유결합된 비-금속 가교원자를 통해 함께 결합된 적어도 두 개의 콘트라스트 증진 금속 원자를 포함하는 조영제.The contrast agent of claim 1, wherein the multinuclear complex comprises at least two contrast enhancing metal atoms bonded together through a covalently bonded non-metallic crosslinking atom. 제1항 또는 2항에 있어서. 상기 다핵 복합체가 리간드에 의해 배위적으로 결합된 적어도 두개의 콘트라스트 증진 금속원자를 포함하는 조영제.The method of claim 1 or 2. A contrast agent comprising at least two contrast enhancing metal atoms in which the multinuclear complex is coordinately bound by a ligand. 제1항 내지 3항 중 어느 한 항에 있어서, 상기 다핵 복합체가 하기 일반식(X)이거나 또는 그의 염인 조영The medium according to any one of claims 1 to 3, wherein the multinuclear complex is the following general formula (X) or a salt thereof. (MaBuAv)x Lw (X)(MaBuAv) x Lw (X) 상기식에서, MaBuAv는 다핵 실재물(entity)이고, 동일하거나 상이한 각 M은 적어도 하나의 원자 B에 공유적으로 결합된 콘트라스트 증진 금속 원자이며, 동일하거나 상이한 각 B는 적어도 두개의 금속원자 M에 공유적으로 결합된 가교 원자이고, 동일하거나 상이한 각 A는 원자 M에 공유적으로 결합된 비 가교 원자이며, 동일하거나 상이한 각 L은 적어도 하나의 금속원자 M에 배위적으로 결합된 리간드이고, n 및 μ는 2또는 그 보다 큰 양의 정수이며, X 및 W는 양의 정수이고, V는 0 또는 양의 정수이다.Wherein MaBuAv is a multinuclear entity, each M, the same or different, is a contrast enhancing metal atom covalently bound to at least one atom B, and each B, the same or different, is covalent to at least two metal atoms M Is a bridging atom bonded to each other, each A, the same or different, is a non-crosslinking atom covalently bonded to the atom M, each L, the same or different, is a ligand coordinatively bound to at least one metal atom M, n and μ Is a positive integer of 2 or greater, X and W are positive integers, and V is 0 or a positive integer. 제4항에 있어서, 각 M은 W또는 Mo 이고, 각 A 및 B는 O, S, Se, Te 또는 양자화되거나 치환된 질소 또는 인 원자이며, N 이 2 내지 6인 조영제.The contrast agent according to claim 4, wherein each M is W or Mo, each A and B is O, S, Se, Te or a quantized or substituted nitrogen or phosphorus atom, and N is 2-6. 제5항에 있어서, 다핵 실재물이 일반식 M2(μ2,B)2B2(여기에서 각 B는 O 또는 S 이고 각 M은 W 또는 Mo이다)인 조영제.The contrast agent according to claim 5, wherein the multinuclear entity is of the general formula M 2 (μ 2 , B) 2 B 2 , wherein each B is O or S and each M is W or Mo. 제5항에 있어서, 다핵 실재물이 하기 일반식중의 한 구성 단위를 포함하는 조영제6. The contrast agent according to claim 5, wherein the multinuclear entity comprises one structural unit of the general formula M3(μ3B) (μ2B)3 M 3 (μ 3 B) (μ 2 B) 3 M4(μ3B)4 M 4 (μ 3 B) 4 M6(μ3B)8 M 6 (μ 3 B) 8 상기 식에서, 각 M은 W또는 Mo이고, 각 B는 O, S, Se, Te 또는 양자화되거나 치화된 질소 또는 인원자이다.Wherein each M is W or Mo and each B is O, S, Se, Te or quantized or quantified nitrogen or phosphorus. 제1항 내지 7항 중 어느 한 항에 있어서, 상기 다핵복합체는 폴리아민 키런트(chelant)를 갖는 복합체인 조영체.8. The contrast medium according to claim 1, wherein the multinuclear complex is a complex having a polyamine chelant. 9. 제8항에 있어서, 상기 키런트가 아미노폴리카복실산 또는 그의 에스테르 또는 아미드 이거나 메크로사이클릭 폴리아실화된-폴리아민인 조영제.9. The contrast agent according to claim 8, wherein said chirant is an aminopolycarboxylic acid or ester or amide thereof or is a macrocyclic polyacylated-polyamine. 제1항 내지 6항 중 어느 한 항에 있어서, 추가로 자유(free) 키런트 또는 생리적으로 허용가능한 염 또는 생리적으로 허용가능한 금속이온을 갖는 그의 약한 복합체를 포함하는 조영제.7. The contrast agent according to any one of claims 1 to 6, further comprising a free complex, or a weak complex thereof having a physiologically acceptable salt or a physiologically acceptable metal ion. 진단용도의 다핵 복합체.Multinuclear complex for diagnostic purposes. 제11항에 있어서, 텅스텐 및/또는 몰리브덴의 복합체.12. The composite of claim 11 wherein tungsten and / or molybdenum are complex. 인간 또는 비-인간인 동물의 영상화에 사용하기 위한 조영제의 제조를 위한 다핵 복합체의 용도.Use of a multinuclear complex for the preparation of contrast agents for use in imaging human or non-human animals. 인간 또는 비인간인 동물의 신체에 생리적으로 허용가능한 다핵복합체를 투여하여, 상기 신체의 적어도 일부분의 영상을 만들어내는 것을 포함하는 인간 또는 비인간 동물 신체의 영상을 만드는 방법.A method of making an image of a human or non-human animal body comprising administering a physiologically acceptable multinuclear complex to the body of a human or non-human animal to produce an image of at least a portion of the body. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019920702350A 1990-03-28 1991-03-27 Contrast agent Ceased KR930700165A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9006977.4 1990-03-28

Publications (1)

Publication Number Publication Date
KR930700165A true KR930700165A (en) 1993-03-13

Family

ID=

Similar Documents

Publication Publication Date Title
ES8703153A1 (en) Magnetic particles for diagnostic purposes.
NO934366D0 (en) Conveniently modified microparticulate contrast agents
DE69122092D1 (en) CONTRAST AGENTS
DE69128791D1 (en) MODIFIED ANTIBODIES WITH CONTROLLED CLEARANCE TIME
BG100192A (en) 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
KR960702447A (en) HEPATOBILIARY MAGNETIC RESONANCE CONTRAST AGENTS
ES2177792T3 (en) COMPLEX POLYMERS IN CASCADA, PROCEDURE FOR PREPARATION AND PHARMACEUTICAL AGENTS CONTAINING THEM.
DE69111821D1 (en) ACTIVE SUBSTANCE DELIVERY VEHICLE SUSPENDED IN A NON-AQUE PERFLUORED CARRIER MEDIUM.
FI881708A0 (en) Nitrogen-containing cyclic ligands, process for their preparation and their use for the preparation of metal complexes and diagnostic compositions containing these complexes
DE69424424D1 (en) PERFLUORO-1H-1H-NEOPENTYL CONTRASTING AGENT AND METHOD FOR ITS USE
KR920000335A (en) Use of Macrocyclic Aminophosphonic Acid Complex as Imaging Agent
IL104059A0 (en) Bicyclopolyazamacrocyclocarboxylic acid complexes,their conjugates,processes for their preparation,and use as contrast agents
MX9207166A (en) BICICLOPOLIAZAMACROCICLOPHOSPHONIC ACIDS, THEIR COMPLEXES AND CONJUGATES, FOR USE AS CONTRAST AGENTS, AND PROCEDURES FOR THEIR PREPARATION.
KR930700165A (en) Contrast agent
ATE228017T1 (en) T1 TIME-WEIGHTED NUCLEAR SPIN TOMOGRAPH OF THE RES ORGANS
RU93053767A (en) Bicyclopolyazamacrocyclophosphonic acids, their complexes and conjugates for use as contrast agents and methods for their preparation
ATE17652T1 (en) L-ALANYL-D-ISOGLUTAMINYL ADAMANTYLAMIDE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL AGENT WITH THIS COMPOUND.
Sapeika Lead EDTA complex-a water-soluble contrast medium
Tweedle Nonionic or neutral?
DE68922686D1 (en) Cyclic, nitrogen-containing ligands, their metal complexes, diagnostic agents containing them and methods for producing the ligands.
JPS6461429A (en) Remedy for cancer
Almén A short survey on experimental studies with relevance to vascular use of metrizamide
Litvinov et al. Experimental estimation of isoniazid hepatotoxicity with bromsulphalein test.
RU93053897A (en) BICYCLOPOLYAZAMACROCYCLOCARBOXYLIC ACID COMPLEXES, THEIR CONJUGATES, PHARMACEUTICAL COMPOSITION, DIAGNOSTIC METHOD, SET AND METHOD FOR PRODUCING
MY141501A (en) Bicyclopolyazamacrocyclophosphonic acids, their complexes and conjugates, for use as contrast agents and processes for their preparation

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920928

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19960117

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19920928

Comment text: Patent Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980926

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 19981130

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19980926

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I